



CardieX subsidiary ATCOR, reaches technology milestone for world-first PPG Sensor Algorithm

29 June 2021: Australian medical technology company, CardieX, announces that its subsidiary, ATCOR, has completed a world-first algorithm for a wearable optical sensor which is able to provide a unique range of cardiovascular health parameters based around ATCOR's patented SphygmoCor® technology.

This major milestone concretizes the technology algorithm foundation for its CONNEQT Band and other wearables partnerships and signals the commercial readiness of ATCOR's wearable health analytics platform, Arty™, into consumer wearable devices.

Currently, no commercially available wearable device offers the range of individualised health parameters that are available on the Arty™ platform which provide unique insights into the heart and surrounding arterial systems.

CardieX CEO Craig Cooper said:

"This is another technology first for the company. We were the first to patent non-invasive central aortic waveform technology. We were the first to obtain FDA clearance (2001) for our "gold standard" non-invasive central blood pressure devices - which has since become the predicate device on which all other attempts to replicate our technology have been based. We were the first and only company to date to validate our technology in a human study. And now we are looking towards being the first to not only launch the worlds-first consumer targeted dual blood pressure monitor, but also the first wearable health band (the CONNEQT Band) with a dual PPG sensor based on our patent application lodged last March."

This milestone announcement closely follows ATCOR having recently been selected by Yale University to participate in a clinical trial focused on assessing effectiveness of aspirin for the prevention of pre-eclampsia in women with elevated blood pressure, leveraging ATCOR's SphygmoCor® XCEL device to non-invasively measure central blood pressure, central arterial pressure waveform, pulse wave velocity, as well as other heart health parameters of study subjects.

Recently, CardieX's CONNEQT subsidiary also announced an agreement with LifeQ, where both companies' joint IP for health biometrics will be included in the upcoming CONNEQT Band. The company also has an agreement with Mobvoi for an upcoming smart wearable device.

For more information please contact:

Investor Relations:

Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au



Media Relations:

Melissa Hamilton melissa.hamilton@mcpartners.com.au

About CardieX

CardieX is a global health technology company. Its ATCOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange (ASX:CDX).